Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Cost of Revenue data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 32.5% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (down 0.52% YoY), and the FY2025 full-year result was $14.5 million, up 31.38% from the prior year.
• Cost of Revenue advanced to $3.3 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.6 million in Q4 2022 to a low of $1.6 million in Q4 2023.
• A 5-year average of $5.4 million and a median of $3.3 million in 2026 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 80.36% in 2022 and tumbled 92.41% in 2023, its largest moves.
• Tracing LGND's Cost of Revenue over 5 years: stood at $21.6 million in 2022, then plunged by 92.41% to $1.6 million in 2023, then surged by 72.88% to $2.8 million in 2024, then gained by 5.46% to $3.0 million in 2025, then rose by 9.39% to $3.3 million in 2026.
• Business Quant data shows LGND's Cost of Revenue at $3.3 million in Q1 2026, $3.0 million in Q4 2025, and $3.8 million in Q3 2025.